Skip to content

Jintupingci mask for patients with lung meridian wind-heat type mild to moderate acne vulgarisa randomized controlled trial

Jintupingci mask for patients with lung meridian wind-heat type mild to moderate acne vulgarisa randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000572
Enrollment
Unknown
Registered
2024-10-18
Start date
2024-05-20
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acne

Interventions

Control Group:Placebo Mask
Treatment Group:Jintupingci mask

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 40 Years

Inclusion criteria

Inclusion criteria: Clinical diagnosis conforms to the diagnostic criteria for common acne with lung meridian wind-heat syndrome; Meets the classification standards of the Pillsbury grading method for grades I and II; Patients with a score of =30 according to the GAGS scoring criteria; Outpatients with common acne aged 14-40 years old; Patients have no cognitive impairments voluntarily accept the trial and commit to actively cooperating with the research having thoroughly read and signed the informed consent form; Adhere to the lifestyle precautions stipulated throughout the study period willing to exclusively use the non-medicated facial cleanser and moisturizer provided by this study and not use other acne treatments.

Exclusion criteria

Exclusion criteria: 1. Individuals who have used topical or oral anti-androgens antibiotics retinoids or other acne treatments within the last month; those who have undergone radiotherapy within the last 2 weeks; 2. Individuals with open wounds on the face that are in the process of healing those with infectious skin diseases; patients with severe primary diseases of the circulatory respiratory or other systems that cannot be controlled with regular medication; individuals with sunburn on the face; 3. Subjects with severe liver kidney cardiovascular respiratory endocrine hematological urinary metabolic central nervous system diseases or autoimmune diseases; 4. Those who are pregnant breastfeeding or under stress conditions such as trauma; 5. Individuals who have participated in other clinical trials within the last month; 6. Anyone who has had a systemic or local allergic reaction to any of the components of this medication. Any individual meeting any of the above criteria will be excluded.

Design outcomes

Primary

MeasureTime frame
The effectiveness rate of the acne severity score;

Secondary

MeasureTime frame
brown zone;sebum;pH;degree of hydration;red zone;brown zone;DLQI;porphyrins;sclererythrin;pores;

Countries

China

Contacts

Public ContactYanping Bai

China-Japan Friendship Hospital

zhi@tsinghua.edu.cn13910758509

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026